Efficacy and Safety of Low-Dose Brexpiprazole for Acute Schizophrenia: Meta-Analysis of Randomized Placebo-Controlled Trials

References

• Messias E, Chen C, Eaton W. Epidemiology of schizophrenia: review of findings and myths. Psychiatr Clin North Am. 2007;30(3):323–338. doi:10.1016/j.psc.2007.04.007
   PubMed Web of Science ®Google Scholar
• McGrath J, Saha S, Chant D, Welham J. Schizophrenia: a concise overview of incidence, prevalence, and mortality. Epidemiol Rev. 2008;30:67–76. doi:10.1093/epirev/mxn001
   PubMed Web of Science ®Google Scholar
• Volavka J, Citrome L. Oral antipsychotics for the treatment of schizophrenia: heterogeneity in efficacy and tolerability should drive decision-making. Expert Opin Pharmacother. 2009;10(12):1917–1928. doi:10.1517/14656560903061309
   PubMed Web of Science ®Google Scholar
• Rössler W, Salize H, van Os J, Riecher-Rössler A. Size of burden of schizophrenia and psychotic disorders. Eur neuropsychopharmacol. 2005;15(4):399–409. doi:10.1016/j.euroneuro.2005.04.009
   PubMed Web of Science ®Google Scholar
• Browne S, Clarke M, Gervin M, Waddington J, Larkin C, O’Callaghan E. Determinants of quality of life at first presentation with schizophrenia. Br J Psychiatr. 2000;176:173–176. doi:10.1192/bjp.176.2.173
   PubMed Web of Science ®Google Scholar
• Hayhurst K, Massie J, Dunn G, Lewis S, Drake R. Validity of subjective versus objective quality of life assessment in people with schizophrenia. BMC Psychiatr. 2014;14:365. doi:10.1186/s12888-014-0365-x
   PubMed Web of Science ®Google Scholar
• Citrome L. A review of the pharmacology, efficacy and tolerability of recently approved and upcoming oral antipsychotics: an evidence-based medicine approach. CNS Drugs. 2013;27(11):879–911. doi:10.1007/s40263-013-0105-7
   PubMed Web of Science ®Google Scholar
• Correll C. From receptor pharmacology to improved outcomes: individualising the selection, dosing, and switching of antipsychotics. Eur Psychiatr. 2010;25:S12–S21. doi:10.1016/s0924-9338(10)71701-6
   PubMed Web of Science ®Google Scholar
• De Hert M, Yu W, Detraux J, Sweers K, van Winkel R, Correll C. Body weight and metabolic adverse effects of asenapine, iloperidone, lurasidone and paliperidone in the treatment of schizophrenia and bipolar disorder: a systematic review and exploratory meta-analysis. CNS Drugs. 2012;26(9):733–759. doi:10.2165/11634500-000000000-00000
   PubMed Web of Science ®Google Scholar
• Leucht S, Cipriani A, Spineli L, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet. 2013;382(9896):951–962. doi:10.1016/s0140-6736(13)60733-3
   PubMed Web of Science ®Google Scholar
• Mauri M, Paletta S, Maffini M, et al. Clinical pharmacology of atypical antipsychotics: an update. EXCLI J. 2014;13:1163–1191.
   PubMed Web of Science ®Google Scholar
• Miyamoto S, Duncan G, Marx C, Lieberman J. Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs. Mol Psychiatry. 2005;10(1):79–104. doi:10.1038/sj.mp.4001556
   PubMed Web of Science ®Google Scholar
• Miyamoto S, Miyake N, Jarskog L, Fleischhacker W, Lieberman J. Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents. Mol Psychiatry. 2012;17(12):1206–1227. doi:10.1038/mp.2012.47
   PubMed Web of Science ®Google Scholar
• Uçok A, Gaebel W. Side effects of atypical antipsychotics: a brief overview. World Psychiatr. 2008;7(1):58–62. doi:10.1002/j.2051-5545.2008.tb00154.x
   PubMed Web of Science ®Google Scholar
• De Hert M, Detraux J, van Winkel R, Yu W, Correll C. Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. Nat Rev Endocrinol. 2011;8(2):114–126. doi:10.1038/nrendo.2011.156
   PubMed Web of Science ®Google Scholar
• Kane J, Barnes T, Correll C, et al. Evaluation of akathisia in patients with schizophrenia, schizoaffective disorder, or bipolar I disorder: a post hoc analysis of pooled data from short- and long-term aripiprazole trials. J Psychopharmacol. 2010;24(7):1019–1029. doi:10.1177/0269881109348157
   PubMed Web of Science ®Google Scholar
• Yoshida K, Takeuchi H. Dose-dependent effects of antipsychotics on efficacy and adverse effects in schizophrenia. Behav Brain Res. 2021;402:113098. doi:10.1016/j.bbr.2020.113098
   PubMed Web of Science ®Google Scholar
• Maeda K, Lerdrup L, Sugino H, et al. Brexpiprazole II: antipsychotic-like and procognitive effects of a novel serotonin-dopamine activity modulator. J Pharmacol Exp Ther. 2014;350(3):605–614. doi:10.1124/jpet.114.213819
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. RXULTI 0.24-4 mg film coated tablets: EU summary of product characteristics; 2018. Available from: https://www.ema.europa.eu. Accessed September 19, 2018.
   Google Scholar
• Otsuka Pharmaceutical Co Ltd. REXULTI® (brexpiprazole) tablets, for oral use: US prescribing information; 2015. Available from: https://www.accessdata.fda.gov. Accessed September 20, 2018.
   Google Scholar
• Otsuka Pharmaceutical Co., Ltd. REXULTI® 1 mg, 2 mg tablets: Japanese prescribing information; 2018. Available from: http://www.pmda.go.jp. Accessed December 19, 2018.
   Google Scholar
• Rexulti® (brexpiprazole) [full prescribing information]; 2020. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/205422s005lbl.pdf. Accessed June 17, 2020.
   Google Scholar
• Ishigooka J, Iwashita S, Tadori Y. Efficacy and safety of brexpiprazole for the treatment of acute schizophrenia in Japan: a 6-week, randomized, double-blind, placebo-controlled study. Psychiatry Clin Neurosci. 2018;72(9):692–700. doi:10.1111/pcn.12682
   PubMed Web of Science ®Google Scholar
• Correll C, Skuban A, Ouyang J, et al. Efficacy and safety of brexpiprazole for the treatment of acute schizophrenia: a 6-week randomized, double-blind, placebo-controlled trial. Am J Psychiatry. 2015;172(9):870–880. doi:10.1176/appi.ajp.2015.14101275
   PubMed Web of Science ®Google Scholar
• Kane J, Skuban A, Ouyang J, et al. A multicenter, randomized, double-blind, controlled Phase 3 trial of fixed-dose brexpiprazole for the treatment of adults with acute schizophrenia. Schizophr Res. 2015;164:127–135. doi:10.1016/j.schres.2015.01.038
   PubMed Web of Science ®Google Scholar
• Study to evaluate the efficacy, safety, and tolerability of oral OPC-34712 and aripiprazole for treatment of acute schizophrenia (STEP 203); 2015. Available from: https://www.clinicaltrials.gov/ct2/show/results/NCT00905307?term=NCT00905307. Accessed August 8, 2022.
   Google Scholar
• Newcomer J, Meyer J, Baker R, et al. Changes in non-high-density lipoprotein cholesterol levels and triglyceride/high-density lipoprotein cholesterol ratios among patients randomized to aripiprazole versus olanzapine. Schizophr Res. 2008;106:300–307. doi:10.1016/j.schres.2008.09.002
   PubMed Web of Science ®Google Scholar
• Newcomer J, Eriksson H, Zhang P, Weiller E, Weiss C. Changes in metabolic parameters and body weight in brexpiprazole-treated patients with acute schizophrenia: pooled analyses of phase 3 clinical studies. Curr Med Res Opin. 2018;34(12):2197–2205. doi:10.1080/03007995.2018.1498779
   PubMed Web of Science ®Google Scholar
• Higgins J, Green S. Cochrane handbook for systematic reviews of interventions Version 5.1. 0 [updated March 2011]; 2012. Available from: http://wwwcochrane-handbookorg. Accessed November 13, 2018.
   Google Scholar
• Moher D, Liberati A, Tetzlaff J, Altman D. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009;339:b2535. doi:10.1136/bmj.b2535
   PubMed Web of Science ®Google Scholar
• Kishi T, Oya K, Matsui Y, et al. Comparison of the efficacy and safety of 4 and 2 mg/day brexpiprazole for acute schizophrenia: a meta-analysis of double-blind, randomized placebo-controlled trials. Neuropsychiatr Dis Treat. 2018;14:2519–2530. doi:10.2147/ndt.s176676
   Web of Science ®Google Scholar
• Fleischhacker W, Kemmler G. The clinical relevance of percentage improvements on the PANSS score. Neuropsychopharmacology. 2007;32(11):2435–2436. doi:10.1038/sj.npp.1301391
   Web of Science ®Google Scholar
• Morosini P, Magliano L, Brambilla L, Ugolini S, Pioli R. Development, reliability and acceptability of a new version of the DSM-IV Social and Occupational Functioning Assessment Scale (SOFAS) to assess routine social functioning. Acta Psychiatr Scand. 2000;101(4):323–329. doi:10.1111/j.1600-0447.2000.tb10933.x
   PubMed Web of Science ®Google Scholar
• Gharabawi G, Bossie C, Turkoz I, Kujawa M, Mahmoud R, Simpson G. The impact of insight on functioning in patients with schizophrenia or schizoaffective disorder receiving risperidone long-acting injectable. J Nerv Ment Dis. 2007;195(12):976–982. doi:10.1097/NMD.0b013e31815c1982
   PubMed Web of Science ®Google Scholar
• Guy W. Manual for the ECDEU Assessment Battery. 2nd ed. Chevy Chase, MD: National Institute of Mental Health; 1970.
   Google Scholar
• DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177–188. doi:10.1016/0197-2456(86)90046-2
   PubMedGoogle Scholar
• Higgins J, Thompson S, Deeks J, Altman D. Statistical heterogeneity in systematic reviews of clinical trials: a critical appraisal of guidelines and practice. J Health Serv Res Policy. 2002;7(1):51–61. doi:10.1258/1355819021927674
   PubMedGoogle Scholar
• Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21(11):1539–1558. doi:10.1002/sim.1186
   PubMed Web of Science ®Google Scholar
• MacKenzie N, Kowalchuk C, Agarwal S, et al. Antipsychotics, metabolic adverse effects, and cognitive function in schizophrenia. Front psychiatr. 2018;9:622. doi:10.3389/fpsyt.2018.00622
   PubMed Web of Science ®Google Scholar
• Kao Y, Liu Y. Effects of age of onset on clinical characteristics in schizophrenia spectrum disorders. BMC psychiatr. 2010;10:63. doi:10.1186/1471-244x-10-63
   PubMed Web of Science ®Google Scholar
• Newcomer J. Metabolic considerations in the use of antipsychotic medications: a review of recent evidence. J Clin Psychiatry. 2007;4:20–27.
   Google Scholar